These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16434834)

  • 1. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects.
    Saglam M; Karakaya O; Esen AM; Barutcu I; Dogan S; Karavelioglu Y; Karapinar H; Akgun T; Esen O; Ozdemir N; Turkmen S; Kaymaz C
    Tohoku J Exp Med; 2006 Feb; 208(2):117-22. PubMed ID: 16434834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy.
    Galderisi M; Cicala S; De Simone L; Caso P; Petrocelli A; Pietropaolo L; Celentano A; Mininni N; de Divitiis O
    Ital Heart J; 2001 Sep; 2(9):677-84. PubMed ID: 11666096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases and hypertension: a link between left ventricular hypertrophy and diastolic dysfunction?
    Karthikeyan VJ; Lip GY
    Tohoku J Exp Med; 2006 Feb; 208(2):93-7. PubMed ID: 16434829
    [No Abstract]   [Full Text] [Related]  

  • 6. [Correlations between blood pressure, left ventricular hypertrophy, and left ventricular diastolic function in hypertensive patients].
    Ito O; Okamoto M; Murakami Y; Nakayama R
    J Cardiol; 1991; 21(4):931-41. PubMed ID: 1844449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular diastolic dysfunction in essential hypertension.
    Avdić S; Mujcinović Z; Asćerić M; Nukić S; Kusljugić Z; Smajić E; Arapcić S
    Bosn J Basic Med Sci; 2007 Feb; 7(1):15-20. PubMed ID: 17489762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T
    J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and predictors of left ventricular hypertrophy in patients with hypertension and normal electrocardiogram.
    Nardi E; Palermo A; Mulè G; Cusimano P; Cerasola G; Rini GB
    Eur J Prev Cardiol; 2013 Oct; 20(5):854-61. PubMed ID: 22556375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
    Michels M; Soliman OI; Kofflard MJ; Hoedemaekers YM; Dooijes D; Majoor-Krakauer D; ten Cate FJ
    JACC Cardiovasc Imaging; 2009 Jan; 2(1):58-64. PubMed ID: 19356534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of hypertension and hypertension-related left ventricle hypertrophy on right ventricle function.
    Tumuklu MM; Erkorkmaz U; Ocal A
    Echocardiography; 2007 Apr; 24(4):374-84. PubMed ID: 17381646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired left ventricular synchronicity in hypertensive patients with ventricular hypertrophy.
    Tan HW; Zheng GL; Li L; Wang ZH; Gong HP; Zhang Y; Zhong M; Zhang W
    J Hypertens; 2008 Mar; 26(3):553-9. PubMed ID: 18300868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure.
    Sam F; Duhaney TA; Sato K; Wilson RM; Ohashi K; Sono-Romanelli S; Higuchi A; De Silva DS; Qin F; Walsh K; Ouchi N
    Endocrinology; 2010 Jan; 151(1):322-31. PubMed ID: 19850745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure.
    Litwin SE; Katz SE; Weinberg EO; Lorell BH; Aurigemma GP; Douglas PS
    Circulation; 1995 May; 91(10):2642-54. PubMed ID: 7743628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular hypertrophy determines the severity of diastolic dysfunction in patients with nonvalvular atrial fibrillation and preserved left ventricular systolic function.
    Moon J; Rim SJ; Cho IJ; Lee SH; Choi S; Chung WJ; Byun YS; Ryu SK; Pyun WB; Kim JY
    Clin Exp Hypertens; 2010; 32(8):540-6. PubMed ID: 21091364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between growth differentiation factor 15 and left ventricular hypertrophy in hypertensive patients and healthy adults.
    Kou H; Jin X; Gao D; Ma R; Dong X; Wei J; Wang X
    Clin Exp Hypertens; 2018; 40(1):8-15. PubMed ID: 29035099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats.
    Iwanaga Y; Aoyama T; Kihara Y; Onozawa Y; Yoneda T; Sasayama S
    J Am Coll Cardiol; 2002 Apr; 39(8):1384-91. PubMed ID: 11955860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An effect of left ventricular hypertrophy on mild-to-moderate left ventricular diastolic dysfunction.
    Kattel S; Memon S; Saito K; Narula J; Saito Y
    Hellenic J Cardiol; 2016; 57(2):92-8. PubMed ID: 27445022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophin.
    Parente JM; Blascke de Mello MM; Silva PHLD; Omoto ACM; Pernomian L; Oliveira IS; Mahmud Z; Fazan R; Arantes EC; Schulz R; Castro MM
    Biochem Pharmacol; 2021 Nov; 193():114744. PubMed ID: 34453903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is echo-determined left ventricular geometry associated with ventricular filling and midwall shortening in hypertensive ventricular hypertrophy?
    Palmiero P; Maiello M; Nanda NC
    Echocardiography; 2008 Jan; 25(1):20-6. PubMed ID: 18186776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.